Author Archives: Scalper1
Watch These 5 IBD 50 Drugmakers Amid Correction
The market is still in a correction, which means that it’s not the best time to buy; but it never hurts to keep an eye on some top performers, such as these hot drugmakers on the IBD 50. Valeant Pharmaceuticals (VRX) said at the start of the month that it will shell out $445 million in a psoriasis drug licensing deal with AstraZeneca (AZN). The drug candidate, brodalumab, may be effective, but AstraZeneca’s old partner Amgen (AMGN) nixed the
Palo Alto Networks CEO: $2 Billion In Two Years
Palo Alto Networks (PANW) is expected late Wednesday to report triple-digit earnings growth for the second consecutive quarter, but revenue growth is forecast to hit record deceleration. For its fiscal Q4 2015, the consensus of 34 analysts polled by Thomson Reuters sees Palo Alto Networks pulling in 25 cents earnings per share ex items, up 127% vs. the year-earlier quarter. Revenue is forecast to increase 44% up to $256.25 million. While still